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ii) Abstract
Study rationale In the Western Cape there are many intrauterine contraceptive devices 
(IUDs) inserted during caesarean section (C/S). Little is known about the long-term outcomes 
in the Metro West area. 
Objective To assess placement of IUDs at C/S and describe follow-up, with a view to 
compile best practice guidelines for insertion and follow-up in our clinic setting. 
Method  A retrospective descriptive audit of clinical records was performed of all 
women who received an IUD at C/S between January and June 2018 at Mowbray Maternity 
Hospital (MMH) and New Somerset Hospital (NSH) in Cape Town.  
Results  There were 2310 and 1376 C/S performed at MMH and NSH respectively. The 
IUD insertion rate was 17.4% (n=402) at MMH and 14.3% (n=197) at NSH. Almost two third of 
insertions were performed at the time of emergency caesarean section (59.1%; n=276). The 
majority of women experienced no immediate complications (84.4%). Only 77 women 
attended follow-up.  The continuation rate at follow-up was 71.6%. The overall expulsion rate 
in hospital and at follow-up was 3%. Strings were visible in 53.2% of patients.  An ultrasound 
was performed in 67.5 % (52/77) of patients. The IUD removal rate at follow-up was 24.7% 
(19/77). 
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Discussion The poor follow-up rate is concerning, and measures must be taken to address 
this. The continuation rate of 71.6% is lower than expected but may have been biased by the 
low follow-up rate. Continuation rates improved with the experience of inserters which 
highlights the importance of training and supervision. 
Conclusion The immediate postpartum period may be the only opportunity to provide 
long acting reversable contraception to some women. In our study population follow-up rates 
are poor and therefore conclusions are difficult to accurately gauge. Measures must be taken 
to improve follow-up.  
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The immediate postpartum use of long acting reversable contraception (LARC) such as the 
intrauterine device (IUD) is an important strategy to increase interpregnancy intervals. It is 
well known that a pregnancy interval of less than two years contributes to increased perinatal 
and maternal morbidity and mortality, with complications ranging from preterm rupture of 
membranes, preterm birth and low birth weight to uterine scar rupture and maternal 
anaemia. [1] The majority of pregnancies occurring after a short interpregnancy interval are 
unplanned. [1] Providing reliable contraception in the immediate postpartum period may be 
the most effective way of preventing unwanted pregnancy and a short interpregnancy 
interval.  
A woman who is not breastfeeding may ovulate by the third week after delivery. Up to 50% 
of women have resumed sexual activity by 6 weeks postpartum, putting them at risk of 
unwanted pregnancy by the time they return for the 6 weeks visit. [2] Those who do not 
return are often socially and economically disadvantaged, and face barriers such as lack of 
transport and stable housing, and difficulty communicating with their health care providers. 
[3] In a randomized controlled trial by Levi et al in 2015, women were randomized to either
receiving the intrauterine device at caesarean section (C/S) or 6 weeks after delivery. IUD 
continuation at the 6 months visit was 83% when placed at C/S, versus 64% when placed at 
the 6 weeks postpartum visit. Of the women randomized to the 6 weeks postpartum 
insertion, 39% never received an IUD - 25% defaulted follow-up, 9% declined and 5% had 
failed placement. [3] Women who choose the IUD are up to ten times less likely to having it 
placed at the 6 weeks visit compared to women receiving it at the time of delivery. [3-5] 
Follow-up rates for the 6-weeks postpartum visit is poor, ranging between 25 and 62%. [1,2] 
This could in part be explained by different follow-up locations and dates for mother and baby 
- a significant barrier to women with new-born babies who just had surgery, and even more
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so for someone with socio-economic difficulties. [6] In a systematic review by Goldstuck and 
Steyn containing 12 studies including 4 randomised controlled trials of delayed versus 
immediate IUD insertion post-delivery, findings were similar - women randomized to delayed 
insertion are significantly less likely to receive the device. [7] By not providing LARC at the 
time of delivery, the most vulnerable women who are most unlikely to return for follow-up 
are being put at risk of unwanted pregnancy. [2,3] By inserting the IUD at delivery, an 
important barrier to LARC namely an additional visit for insertion is removed.  
Insertion of the IUD during C/S is easier, less time-consuming, less painful and requires less 
instrumentation than interval insertion. There is no risk of primary perforation as the insertion 
is performed under direct vision. [7-10] Very few contraindications exist, and most women 
are eligible for its use.  The timing is ideal since the patient is in hospital with adequate 
counselling and expertise available, and she is motivated for effective family planning. Efficacy 
of the copper-containing IUD (Pearl index = 0.6) is on par with female sterilization (Pearl index 
= 0.5), and thus could be offered as a reversable alternative. [11] It is a fit and forget method, 
since once it is placed its effect is not dependent on any patient action, and even if the patient 
does not return for her 6 week visit, she will have protection against pregnancy provided that 
the device stays in place. The IUD is a hormone-free method of contraception, and therefore 
does not have any effect on breastmilk production or infant growth, with no maternal 
systemic effects.[12,13] In contrast to some other LARCs, the efficacy of the IUD is not 
affected by medication such as antiretroviral therapy, antituberculosis treatment and anti-
epileptics. In addition, it is immediately effective, its effect can last for up to 10 years, and it 
requires active discontinuation as compared to most other methods. Insertion at the time of 
C/S eliminates a 6-week waiting period for contraception, as well as an additional office visit. 
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In a prospective cohort study by Heller et al, more than one in eight women chose this method 
of contraception when routinely offered before elective C/S. [14] The study confirmed a low 
complication rate and an expulsion rate in keeping with that of insertion in women who were 
not postpartum. Satisfaction rates were high, and continuation rates remained high at 12 
months post-insertion. It thus proved to be convenient and cost-effective for both women 
and health services.    
Complications include malpositioning, expulsion, perforation, embedment, infection and 
failure. Expulsion rates appear to be lower during intra-operative placement (3.9-10.9%) as 
compared to early insertion after normal delivery (25-30%), but it is slightly higher than the 
expulsion rate during interval insertions in most studies. [2,3,6,8,9,12,14-16] Expulsion 
usually occurs within the first 3 weeks post-insertion. [3,15].  
The most common immediate postinsertion complication was febrile morbidity (2%) in an 
observational study by Singal et al, however the majority of these women had a hospital stay 
of less than 4 days. [6]  
Post-insertion infection rates are low, ranging between 0 and 0.8%. [9,10,14] The incidence 
of a vaginal discharge is around 7%. [10,16] Failure rates are consistently less than 1% in the 
literature. [6,7,9,16-18] 
In a study by Chawla et al, malpositioning after vaginal delivery insertion was 62% versus 28% 
after operative insertion. Where malpositioning occurred, adverse effects increased, and 
continuation rates decreased. [15] Gross malpositioning may be detected by a strings check, 
although this is not always the case. Women may return with side-effects such as menstrual 
irregularities, pain or unintended pregnancy, or it may be detected by ultrasound. [5] In some 
situations, malpositioned IUDs may be asymptomatic. Malpositioned IUDs however presents 
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more commonly with complications than normally placed IUDs. [13,15,16] Identifying a 
malpositioned IUD presents an opportunity to offer the patient early repositioning or close 
follow-up, and in this way lower the complication rate and improve compliance. [13;16] 
Although there is no consensus regarding the threshold measurement that would classify an 
IUD as being correctly placed, most studies describe a distance less than 15 mm from the 
fundus as acceptable. It must be positioned linearly in the uterine cavity with the horizontal 
arms reaching laterally towards the cornua. [9,15] Routine scanning at follow-up is not the 
norm and may lead to unnecessary anxiety and removal in some instances, but all women 
who are symptomatic or where the strings cannot be seen, should have an ultrasound to 
locate the IUD. [13;16;19] 
The incidence of lost strings after intra-operative IUD insertion varies, and it can be as high as 
50 - 70%. [7,9,14,20] This is increased when compared to interval insertion and can be 
explained by the method of insertion – the strings usually are not introduced into the cervical 
canal at the time of caesarean section. It is also dependant on the surgical technique and the 
type of IUD used – e.g. the Cu380A has short strings, whereas the Nova T has long strings. The 
majority (91.8%) of lost strings can easily be found in the cervical canal.[17] Anchoring the 
device, guiding the strings into the cervical canal and using devices with longer strings are all 
techniques to reduce the incidence of lost strings. In the abovementioned study by Heller et 
al, the incidence of lost strings in women receiving the IUD at C/S was 50%, and it was 
recommended by the authors that when intra-caesarean IUD placement is offered, rapid 
access to ultrasound at follow-up should be considered. [14] 
According to the Population Reference Bureau Family Planning Worldwide Data Sheet 2019, 
54% of women in South Africa use some form of contraception. [21] Despite this, 62% of 
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women report that their last pregnancy was unwanted or unplanned. [22] This indicates the 
still unmet need for the correct method of contraception being used. The lifetime risk of 
maternal death in South Africa is one in 300, and reliable contraception plays a crucial role in 
lowering this risk. [21] The reported use of the IUD is 1.2% in South Africa, which correlates 
with user rates in other less developed countries. [21] Methods more commonly used by 
women are the injectable contraceptive (23.9%), male condom (8.8%), oral contraceptive pill 
(8.4%), female sterilization (7.7%) and subdermal implants (3.3%).[21] The use of LARCs is 
thus much lower compared to other methods, even though the risk of unintended pregnancy 
is twenty times higher when women are using short-acting methods. This is often due to 
incorrect and inconsistent use with these methods.[23]  
In a South African survey in 2006 about the knowledge, attitudes and practices surrounding 
the IUD in public sector clinics, barriers to inserting the IUD included concerns regarding pelvic 
inflammatory disease, misinformation, and lack of sufficient knowledge and training in terms 
of counselling and insertion. [24] Another finding was that South African women are 
interested in learning more about the IUD and possibly using it. In a cross-sectional survey of 
538 women in the public sector in Cape Town (2009), most women wanted to wait at least 3 
years before their next pregnancy, or they were not sure if they wanted another child. Few of 
them reported having been told about the IUD, and knowledge about the method were 
lacking. Fear of the procedure of inserting an IUD was another barrier to insertion. [22] The 
advantage of intra-caesarean insertion in improving the uptake in these women is evident.  
Postpartum IUD insertion is a relatively new practice in the Western Cape, with insertion at 
C/S increasing around 2014, and after vaginal delivery around 2015. With C/S rates still on the 
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rise in South Africa and worldwide, intra-caesarean IUD insertion provides the ideal 
opportunity to enable women to achieve healthy inter-pregnancy intervals. 
There are currently many IUDs inserted during C/S in the Western Cape, but little is known 
about the long-term outcomes in these patients in terms of side-effects, continuation rates, 
patient satisfaction and failure rates. Up till now, there is surprisingly little published data on 
the factors influencing continuation rates – specifically the indication for the C/S, cervical 
dilatation, previous uterine surgery, the experience of the inserter and the HIV status of the 
woman.  
Follow-up and self-audit are vital in measuring the success of an IUD program and improving 
outcomes. Challenges at follow-up include poor attendance rates, varying healthcare 
provider skills, time, and financial constraints in conducting telephonic interviews, ever-
changing patient contact details, and the management of missing strings including availability 
of thread-retrievers and imaging. Where strings are missing, a second visit may be needed as 
ultrasound machines and/or operator experience may be lacking.   [2;3;5;7;8;10;14;16] In the 
study by Levi et al, only 48% of women returned for follow-up. Of these women, 72% required 
an ultrasound, and 26% did not return for their ultrasound appointment. Only 47% of patients 
were reachable by phone, email or in person by 6 months. [2]  
The aim of this study is to assess the practice of placement of IUDs at caesarean section and 
describe follow-up, with a view to compile best practice guidelines for insertion and follow-
up in our clinic setting in the Metro West area of Cape Town. We further aim to investigate 
factors influencing placement of the IUD and continuation rates. Improving our knowledge 
about outcomes will help guide us in how to improve counselling and follow-up in these 
women. 
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about outcomes will help guide us in how to improve counselling and follow-up in these 
women. 
It is a retrospective descriptive audit of clinical records of all patients who received the IUD at 
elective and emergency C/S in the 6-month period between January and June 2018 at 
Mowbray Maternity Hospital (MMH) and New Somerset Hospital (NSH) in Cape Town, South 
Africa. Women with chorioamnionitis, puerperal sepsis, premature or prolonged rupture of 
membranes and postpartum haemorrhage (PPH) at the time of insertion were excluded. The 
available IUD in the state sector at the time was the Nova T 380 (Bayer), which is registered 
for 5 years of use. Hormone-containing IUDs were not offered in the state sector for the 
purpose of contraception due to cost. 
Theatre registers were used to obtain the names and file numbers of all patients who received 
the IUD during C/S between 1 January to 30 June 2018. The obstetric records were obtained, 
and patient demographics and clinical details were recorded (see table I and II p.32-33).  
The folder numbers and names were cross checked at GSH and NSH to assess whether the 
women attended any follow-up visits at the relevant hospitals (Patients who had the IUD 
inserted at MMH  followed up at Groote Schuur Hospital (GSH), and patients who received 
the IUD at NSH followed up at NSH). Follow-up records were reviewed to assess findings at 
follow-up, including symptoms, string check findings, whether an ultrasound was performed, 
ultrasound findings, removal and expulsion rates, and reasons for removal of the IUD. The HIV 
status, parity, amount of previous C/Ss, cervical dilatation, indication for the C/S and seniority 
of the IUD inserter and continuation rates were recorded.  Information was entered on a data 
capture instrument (see appendix 1). 
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The aim was a sample size of 63 patients who attended follow-up at each hospital. This sample 
size was based on a follow-up rate of 20%, a 95% confidence interval and a power of 80% if 
60 IUDs are placed per month at each hospital. 
Data was entered on a Microsoft Excel spread sheet (after removal of patient names) and 
imported into a statistics software package (Stata version 13.1, Copyright 1985-2013 
Statacorp, LP, USA) for analysis. 
Institutional consent was obtained from all relevant hospitals, as well as the Western Cape 
Department of Health (Ref no WC_201810_013). Patient consent was not necessary as this 
was a retrospective chart review. Ethics approval was obtained from the Health Science 
Faculty Human Research Ethics Committee of the University of Cape Town (Ref no 542/2018). 
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Background: In the Western Cape there are many intrauterine contraceptive devices (IUDs) 
inserted during caesarean section (C/S). Little is known about long-term outcomes in the 
Metro West region of Cape Town. 
Objective: To assess placement of IUDs at C/S and describe follow-up, with a view to compile 
best practice guidelines for insertion and follow-up in our clinic setting. 
Method: A retrospective descriptive audit of clinical records was performed of all women who 
received an IUD at C/S between January and June 2018 at Mowbray Maternity Hospital 
(MMH) and New Somerset Hospital (NSH) in Cape Town. 
Results: There were 2310 and 1376 C/Ss performed at MMH and NSH respectively. The IUD 
insertion rate was 17.4% (n=402) at MMH and 14.3% (n=197) at NSH. Almost two third of 
insertions were performed during emergency C/S (59.1%; n=276). The majority of women 
experienced no immediate complications (84.4%). Only 77 women attended follow-up. The 
continuation rate at follow-up was 71.6%. The overall expulsion rate in hospital and at follow-
up was 3%. Strings were visible in 53.2 % of patients. An ultrasound was performed in 67.5 % 
of patients. The IUD removal rate at follow-up was 24.7%. 
Conclusion: The immediate postpartum period may be the only opportunity to provide long 
acting contraception to some women. In our study population follow-up rates are poor and 
therefore conclusions cannot be accurately gauged. Measures must be taken to improve 
follow-up. 
Key words: contraceptive IUDs, caesarean section, best practices, postpartum, outcome 
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Introduction 
The immediate postpartum insertion of long acting reversable contraceptives (LARCs) such as 
the intrauterine contraceptive device (IUD) is an important strategy to increase 
interpregnancy intervals. Pregnancy intervals of less than two years significantly contributes 
to increased perinatal and maternal morbidity and mortality, with complications ranging from 
preterm rupture of membranes, preterm birth and low birth weight to uterine scar rupture 
and maternal anaemia. [1] The majority of pregnancies occurring after a short interpregnancy 
interval are unplanned. [1] Providing reliable contraception in the immediate postpartum 
period may be the most effective way of preventing unwanted pregnancy and short 
interpregnancy intervals.  
A woman who is not breastfeeding may ovulate by the third week after delivery. Up to 50% 
of women have resumed sexual activity by 6 weeks postpartum, putting them at risk of 
unwanted pregnancy by the time they return for the 6 weeks visit. [2] Those who do not 
return are often socially and economically disadvantaged, and face barriers such as lack of 
transport and stable housing, and difficulty communicating with their health care providers. 
[3] Women who choose the IUD are up to ten times less likely to having it placed at the 6
weeks visit compared to women receiving it at the time of delivery. [3-7] Follow-up rates for 
the 6-weeks postpartum visit is poor, ranging between 25 and 62%. [1,2] This could in part be 
explained by different follow-up locations and dates for mother and baby - a significant 
barrier to women with new-born babies who just had surgery, and even more so for someone 
with socio-economic difficulties. [6] By not providing LARC at the time of delivery, the most 
vulnerable women who are most unlikely to return for follow-up are being put at risk of 
24 
unwanted pregnancy. [2,3] By inserting the IUD at delivery, an important barrier to LARC 
namely an additional visit for insertion is removed. 
Intra-caesarean insertion is easier, less time-consuming, less painful and requires less 
instrumentation than interval insertion. There is no risk of primary perforation as the insertion 
is performed under direct vision. [7-10] Few contraindications exist, and timing is ideal since 
counselling and expertise are available and the patient is motivated for family planning. 
Efficacy of the copper-containing IUD (Pearl index = 0.6) is on par with female sterilization 
(Pearl index = 0.5), and thus could be offered as a reversable alternative. [11] Once it is placed 
its effect is not dependent on any patient action, and even if the patient does not return for 
her 6-week visit, she is protected against pregnancy provided that the device stays in place. 
The hormone-free IUD does not have any effect on breastmilk production or infant growth, 
and has no maternal systemic effects.[12,13] In contrast to some other LARCs, the efficacy of 
the IUD is not affected by antiretroviral, antituberculosis or anti-epileptic therapy. In addition, 
it is immediately effective, can last for up to 10 years, and requires active discontinuation. 
Insertion at the time of C/S eliminates a 6-week waiting period for contraception and an 
additional office visit.   
In a prospective cohort study by Heller et al, more than one in eight women chose this method 
of contraception when routinely offered before elective C/S. [14] The study confirmed a low 
complication rate and an expulsion rate in keeping with that of insertion in women who were 
not postpartum. Satisfaction and continuation rates remained high at 12 months post-
insertion, and it proved to be convenient and cost-effective for both women and health 
services.    
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Complications include malpositioning, expulsion, perforation, embedment, infection and 
failure. Expulsion rates are lower during intra-operative placement (3.9-10.9%) as compared 
to early insertion after normal delivery (25-30%), but it is slightly higher than the expulsion 
rate after interval insertions in most studies. [2,3,6,8,9,12,14-16] Expulsion usually occurs 
within the first 3 weeks post-insertion. [3,15].  
Post-insertion infection is uncommon, ranging between 0 and 0.8%. [9,10,14] The incidence 
of a vaginal discharge is 7%. [10,16] Failure rates are consistently less than 1%. [6,7,9,16-18] 
The commonest postinsertion complication after C/S was febrile morbidity (2%) in an 
observational study by Singal et al, but most of these women had a hospital stay of less than 
4 days. [6] 
In a study by Chawla et al, malpositioning after vaginal delivery insertion was 62% versus 28% 
after operative insertion. Where malpositioning occurred, adverse effects were increased and 
continuation rates decreased. [15] Gross malpositioning may be detected by a strings check, 
although this is not always the case. Women may return with side-effects such as menstrual 
irregularities, pain or unintended pregnancy, or it may be detected by ultrasound. [5] In some 
situations, malpositioned IUDs may be asymptomatic. Identifying a malpositioned IUD 
presents an opportunity to offer early repositioning or close follow-up, and thereby lower 
complication rates and improve compliance. [13;16] Although no consensus exists regarding 
the threshold measurement that would classify an IUD as being correctly placed, most studies 
describe a distance less than 15 mm from the fundus as acceptable. It must be positioned 
linearly in the uterine cavity with the horizontal arms reaching laterally towards the cornua. 
[9,15] Routine scanning at follow-up is not the norm, but all women who are symptomatic or 
where the strings cannot be seen, should have an ultrasound to locate the IUD. [13;16;19] 
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The incidence of lost strings after intra-operative IUD insertion can be as high as 50 - 70%. 
[7,9,14,20] This can be explained by the method of insertion – the strings usually are not 
introduced into the cervical canal at the time of C/S. It is also dependant on the surgical 
technique and the type of IUD used – e.g. the Cu380A has short strings, whereas the Nova T 
has long strings. The majority (91.8%] of lost strings can easily be found in the cervical canal. 
[17] Anchoring the device, guiding the strings into the cervical canal and using devices with
longer strings are all techniques to reduce the incidence of lost strings. Some authors 
recommended rapid access to ultrasound at follow-up as an important consideration when 
offering intra-caesarean IUD placement. [14] 
Even though fifty-four percent of women in South Africa use some form of contraception, 
62% of their last pregnancies was unwanted or unplanned. [21,22] This indicates the still 
unmet need for the correct method of contraception being used.  The reported use of the IUD 
in South Africa is 1.2%, which correlates with user rates in low-income countries. [21] The use 
of LARCs is much lower than other methods, even though the risk of unintended pregnancy 
is twenty times higher when women are using short-acting methods. [23] A South African 
survey in 2006 found that barriers to IUD insertion included concerns regarding pelvic 
inflammatory disease, misinformation, and lack of sufficient knowledge and training in terms 
of counselling and insertion. [24] South African women showed interested in learning more 
about the IUD and possibly using it. In a cross-sectional survey of 538 women in the public 
sector in Cape Town (2009), most women want to wait at least 3 years before their next 
pregnancy or are unsure if they want another child. Few reported having been told about the 
IUD, and knowledge were lacking. Fear of the insertion procedure was another barrier to 
using the method. [22] The benefit of intra-caesarean placement in improving uptake in these 
women is evident.  
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Postpartum IUD insertion is a relatively new practice in the Western Cape, with insertion at 
C/S increasing around 2014, and after vaginal delivery around 2015. With rising C/S rates 
locally and worldwide, intra-caesarean IUD insertion provides the ideal opportunity to enable 
women to achieve healthy inter-pregnancy intervals. 
There are currently many IUDs inserted during C/S, but little is known about the long-term 
outcomes in the Metro West area. Up till now, surprisingly little data has been published on 
the factors influencing continuation rates – specifically the indication for the C/S, cervical 
dilatation, previous uterine surgery, the experience of the inserter and the HIV status of the 
woman.  
Follow-up and self-audit are vital in measuring the success of an IUD program and improving 
outcomes. Challenges at follow-up include poor attendance rates, varying healthcare 
provider skills, time and financial constraints in conducting telephonic interviews, ever-
changing patient contact details, and the management of missing strings including availability 
of thread-retrievers and imaging. Where strings are missing, a second visit may be needed as 
ultrasound machines and/or operator experience may be lacking.   [2;3;5;7;8;10;14;16] In the 
study by Levi et al, only 48% of women returned for follow-up. Of these women, 72% required 
an ultrasound, and 26% did not return for their ultrasound appointment. Only 47% of patients 
were reachable by phone, email or in person by 6 months. [2]  
The aim of this study is to assess the practice of placement of IUDs at C/S and describe follow-
up, with a view to compile best practice guidelines for insertion and follow-up in our clinic 
setting in the Metro West area of Cape Town. 
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Methods 
A retrospective descriptive audit of clinical records was performed of all women who received 
an IUD at C/S between January and June 2018 at Mowbray Maternity Hospital (MMH) and 
New Somerset Hospital (NSH) in Cape Town. Women with chorioamnionitis, puerperal sepsis, 
premature or prolonged rupture of membranes and postpartum haemorrhage (PPH) at the 
time of insertion were excluded. The available IUD in the state sector at the time was the 
Nova T 380 (Bayer). 
Theatre registers were used to obtain the names and file numbers of all patients who received 
the IUD during emergency and elective C/S. Obstetric records were obtained and patient 
demographics and clinical details identified (see tables I and II).  
The folder numbers and names were cross checked at Groote Schuur Hospital (GSH) and NSH 
to assess whether the women attended any follow-up visits at the relevant hospitals (Patients 
who had the IUD inserted at MMH  followed up at GSH, and patients who received the IUD at 
NSH followed up at NSH). Follow-up findings were recorded. The aim was a sample size of 63 
patients attending follow-up at each hospital. This sample size was based on a follow-up rate 
of 20%, a 95% confidence interval and a power of 80% if 60 IUDs are placed per month at each 
hospital. 
Data was entered on a Microsoft Excel spread sheet after removal of names and folder 
numbers and imported into a statistics software package (Stata version 13.1, Copyright 1985-
2013 Statacorp, LP, USA) for analysis. 
Institutional consent was obtained from all relevant hospitals, as well as the Western Cape 
Department of Health (Ref no WC_201810_013). 
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Ethics approval was obtained from the Health Science Faculty Human Research Ethics 
Committee of the University of Cape Town (Ref no 542/2018). 
Results 
There were 2310 and 1376 C/S performed at MMH and NSH respectively from January to June 
2018. The IUD insertion rate was 17.4% (n=402) at MMH and 14.3% (n=197) at NSH. Of the 
patients who had an IUD inserted, 132 folders were either lost or excluded due to poor note 
keeping or exclusion criteria. We could therefore only assess 467 records (figure 1). 
The median age at insertion was 27 years (p50=27; IQR=8), and the median parity 2 (p50=2; 
IQR=1). Most women were unemployed (63.2%; 295/467) and single (60.8%; 284/467) (table 
I). Almost two third of insertions were done at the time of emergency C/S (59.1%; 276/467). 
In 7 cases it was unclear if the C/S was an elective or emergency (table II). A family planning 
discussion was documented in the antenatal period with 84% (392/467) of patients, during 
labour in 2% (7/467) and at the time of C/S in 13% (61/467). The commonest indications for 
the emergency C/S were fetal distress (49.7%), one previous C/S (12.76%) and failure to 
progress (10.3%). 
 Of patients choosing the IUD, 40% (187/467) had no previous C/S, 41.8% (195/467) had one 
previous C/S, and 18% (84/467) had more than one.  The HIV positive rate amongst the study 
population was 27.8% (130/467), with 85.4% (111/467) of these women having a viral load of 
less than a thousand (table II). 
Immediate complications (figure 2) were defined as complications occurring whilst still in 
hospital and which could possibly have been attributed to the IUD. Most women experienced 
no immediate side-effects (84.4%, 394/467). Complications included unexplained tachycardia 
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(10.7%, 50/467), unexplained temperature (3%, 14/467), PPH (1.3%, 6/467), expulsion (1.1%, 
5/467), minor wound sepsis (0.6%, 3/467), and endomyometritis (0.4%, 2/467). One of the 
women with endomyometritis (0.2%) had a hysterectomy.  She had an evacuation of her 
uterus 6 weeks post-delivery for secondary PPH. Three days later she had a hysterectomy and 
histology confirmed endomyometritis. 
The mean amount of days spent in hospital post-delivery were 3.27 (min 2, max 12, 95% CI 
3.19-3.35).  
Only 16.5% (77/467) of women attended follow up of whom 68 (88.3%) attended at the 
designated appointment and 9 (11.6%) attended elsewhere. The follow-up rate at NSH 
(18.4%, 25/136) was slightly better than at GSH (13%, 43/331). There was no difference in the 
mean age and parity between patients who attended follow up (27.4; 2.3) and those who did 
not attend (27.2; 2.3). The continuation rate at follow up was 71.6% (53/74), specifically 
60.5% (23/38) after emergency C/S, and 82.8% (24/29) after elective C/S (p=0.049) (figure 3, 
table VII). Of the 49 MMH patients who followed up, 34 (69.4%) continued with their IUD, and 
of the 28 NSH patients who followed up, 19 continued (67.9%) (p=0.889) (figure 4). In 3 of the 
women attending follow up it was not clear from the case notes whether they continued with 
their IUD or not (table III). The commonest symptoms at follow up were vaginal discharge 
(26%; 20/77), pain (11.7%; 9/77), expulsion (11.7%; 9/77), abnormal bleeding (6.5%; 5/77), 
and protruding strings (6.5%; 5/77). There were no perforations. Patients were asymptomatic 
in 51.9% (40/77) of cases (figure 5). In most patients complaining of a discharge no antibiotic 
was prescribed and reassurance was adequate.   
One woman fell pregnant post-insertion. She was a 27-year old para 4 who defaulted follow-
up after IUD-insertion at emergency C/S. She returned three months later pregnant with 
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twins. No IUD was seen on ultrasound. She had a negative laparoscopy for abdominal pain in 
the second trimester, and subsequently had a C/S and tubal ligation early in 2019. The total 
expulsion rate after emergency C/S was 3.26% (9/276) and after elective C/S 2.17% (4/184) 
(p=0.576 table VI, fig.7). In one case it was unsure if it was an emergency or elective C/S). 
Strings were visible at follow up in 53.2 % (41/77) of patients.  An ultrasound was performed 
in 67.5 % (52/77) of patients - 79.6% (39/49) of patients at GSH and 46.4% (13/28) at NSH. 
The IUD was normally placed in 63.5 % (33/52) of cases where ultrasound was performed. 
Malpositioning (IUD distance of more than 20 mm from fundus and/or abnormally positioned 
in the cavity) occurred in 23% (12/52) of cases, and no IUD was seen in 5.8% (3/52) (figure 7). 
The IUD removal rate at follow up was 24.7% (19/77). Reasons for removal included 
symptoms (6/19; 31.6%), symptoms and ultrasound (5/19; 26.3%), ultrasound alone (5/19; 
26.3%), clinical malpositioning (IUD stem visible on speculum) (1/19; 5.3%), and patient 
request (1/19; 5.3%). In one case the reason for removal was unclear in the notes (figure 9). 
Two women opted for IUD reinsertion at the same visit, the others chose a different 
contraceptive method (table III). 
Surgeons with the best continuation rates were the registrars (67.6%; 23/34), followed by the 
medical officers (59.3%; 16/27), the community service doctors (57.1%; 4/7), and interns 
(33.3%; 1/3) In 8 women who attended follow-up it was unclear from the notes who the 
inserter was (figure 10; table 4).  
The amount of previous caesarean sections (p=0.053), degree of cervical dilatation (p=0.249) 
and HIV status (p=0.474) had no statistically significant effect on continuation rates. 
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Tables: 
Demographics n (%) 
Age n = 467 
    15-19 33 (7.1) 
    20-24 120 (25.7) 
    25-29 165 (35,3) 
    30-34 102 (21.8) 
    35-39 43 (9.2) 
    40+ 4 (0.9) 
Employment 
    Unknown 17 (3.6) 
    Employed 155 (33.2) 
    Unemployed 295 (63.2) 
Income 
    Unknown 2 (0.43) 
    < R70 000 p/a 415 (88.9) 
    R 70 0000 - R250 000 
p/a 33 (7.1) 
> R250 000 p/a 13 (2.8) 
    Private 4 (0.9) 
Marital status 
    Unknown 4 (0.9) 
    Single 284 (60.8) 
    Married 137 (29.3) 
    Partner 42 (9) 
Table I. Patient demographics 
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CLINICAL PATIENT DATA 
n (%) 
Parity post-delivery n=467  
1 107 (22.9) 
2 176 (37.7) 
3 139 (29.8) 
4 36 (7.7) 
5 4 (0.9) 
6 1 (0.2) 
    Unknown 4 (0.9) 
Caesarean section 
    Elective 184 (39.4) 
    Emergency 276 (59.1) 
    Unknown 7 (1.5) 
Previous CS 
    None 187 (40.0) 
    1 195 (41.8) 
    2 73 (15.6) 
    more than 2 4 (0.9) 
    Unknown 7 (1.5) 
Booking 
    Unbooked 2 (0.4) 
    Booked 458 (98.1) 
    Unknown 7 (1.5) 
HIV status 
Unknown 2 (0.4) 
    Positive 130 (27.8) 
    Negative 335 (71.7) 
Viral load 
    Unknown 9 (6.9) 
    <1000 111 (85.4) 
>1000 10 (7.7) 
Table II: Clinical patient data 
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Findings at Follow-up 77 
Complete expulsions found at F/U 
appointment 4 
Removals (partial expulsions + other) 19 
Re-insertions 2 
Unknown (whether patient continues or not) 3 
Total continuation 53 
Table III: Continuation rates 
Seniority of surgeon Number* (n=79)** % 
Registrar 23/34 67.6 
Medical Officer 16/27 59.3 
Community Service doctor 4/7 57.1 
Intern 1/3 33.3 
Inserter unknown  7/8 87.5 
*Number of patients
**In-hospital expulsions/removals(5) + pts at F/U(77) minus unknown outcomes at F/U(3) = 79 
Table IV: Continuation rate by seniority/experience of surgeon performing insertion 
Type of expulsion n=467 
Expulsions/removals in hospital 5 
Partial expulsions* at F/U 5 
Complete expulsions at F/U 4 
Total 14 
Overall expulsions = immediate(5) + at follow-up(9) = 14/467 = 
3% 
*IUD stem visible on speculum exam or partial expulsion on ultrasound









@ F/U Total 
Emergency C/S 276 4 5 9 
Elective C/S 184 1 3 4 
Unknown 7 0 1 1 
Total 467 5 9 14 
Table VI: Expulsion vs C/S type 
Column1 Column2 Column3 Column4 Column5 
Emergency C/S Elective C/S Unknown Total 
Continued 22 23 6 51 
Discontinued 15 5 1 21 
Unknown 2 1 0 3 
Reinserted 1 1 0 2 
Total 40 30 7 77 
Table VII: Continuation vs C/S type 
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Figures: 
Caesarean sections performed 
MMH: 2310 NSH: 1376 
 
MMH: 402 (17.4%) NSH: 197 (14.2%) 




GSH: 43 (13%) NSH: 25 (18.4%) Elsewhere: 9 (1.9%) 
Figure 1: Data collection summary 
Caesarean sections performed 
MMH: 2310 NSH: 1376 
IUDs inserted 
MH: 40  (17.4%) NSH: 197 (14.3 ) 
Folders excluded: 132 
n=467 
MMH: 331 NSH: 136 
Follow up 
(n=77)
GSH: 43 (13%) NSH: 25 (18.4%) Elsewhere:  (1.9%) 
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Figure 2: Immediate complications that could possibly be attributed to the IUD. 












































Discontinuation rate vs CS type 
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Figure 4: Continuation rate at 6 weeks follow-up. 





















































*Partial expulsion: expulsion identified by IUD stem visible on speculum or by ultrasound
Figure 6: Expulsion 
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Figure 8: Ultrasound findings at follow-up 










Ultrasound findings at Follow-up








Reasons for removal at follow-up
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Surgeon vs continuation rate
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Discussion 
Patients who opted for intra-caesarean placement were mostly between the age of 20 and 
34, with the highest uptake in the 25-29 years age group. The uptake (14.3 – 17.4%) is similar 
in other studies. [21] The high proportion of single, unemployed women choosing the IUD 
confirm the need for LARCs in these women. The low rate (0,4%) of unbooked women is 
encouraging, and we can assume that contraceptive methods would have been discussed 
with most women at some stage during their pregnancy.  
The high percentage of patients who did not attend follow-up (83.5%) is concerning. The 
slightly better follow-up rate at NSH might be because patients could follow up at the place 
of insertion and thus were familiar with the setup, whereas MMH patients attend follow-up 
at GSH. The employed proportion of women who followed up was almost double that of the 
unemployed. This underscores the financial barrier to follow-up, and rates might improve if 
patients could follow up closer to their homes. Follow-up rates in the literature ranges 
between 48 and 88.5%, but this was in prospective studies where patients were counselled 
extensively and may have received remuneration for transport. [8;21;22;24] Some of our 
patients may have attended in the private sector or at their local clinic, in which case we 
cannot see it on the hospital computer system. A study exploring reasons for the poor follow-
up rates and whether women attend elsewhere may be insightful. The continuation rate of 
71.6% is slightly lower than expected. In the literature it ranges between 80 and 91%. 
[2;8;9;13;21;23] One could postulate that women would be more likely to attend follow-up if 
they experienced side-effects or wanted the IUD removed, which would make the 
complication and removal rate higher in the follow-up than in the lost-to-follow-up group. 
However, this is our opinion and cannot be accurately ascertained.  
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Most women (84.4%) experienced no immediate side-effects, which is reassuring. Many of 
the side-effects could also be attributed to the normal inflammatory response to surgery or 
pain, e.g. a transient tachycardia (10.7%) and/or unexplained temperature (3%). The 
immediate expulsion rate was 1.1 %. Four out of five immediate expulsions were after 
emergency C/S – some directly post-operative in the theatre or recovery room and some 
during the hospital stay. It may be postulated that cervices often are dilated in the case of 
emergency C/S, and that may explain the increased rate of expulsion thereafter. The 
incidence of endomyometritis (0.4%) and minor wound sepsis (0.6%) were low. Major 
complications were rare – only one woman (0.2%) had a hysterectomy secondary to 
endomyometritis. It is difficult to prove that the IUD caused the endomyometritis although it 
may have been a contributing factor.  Hysterectomy does not appear to be increased after 
intra-caesarean IUD insertion and there were no maternal deaths in our patient sample. 
Immediate complications or side-effects did not prolong hospital stay, which is important if 
cost, resources, and patient satisfaction are considered. 
The commonest side-effect at follow-up was a vaginal discharge (26%), with pain the second 
most common symptom (11.7%).  In the literature pain and bleeding are the most common 
symptoms, with an incidence of up to 55%. [8] The high incidence of vaginal discharge could 
be physiological, since very few patients required antibiotics. 
In 40.3% of cases IUD strings were not visible at follow-up which was expected. Visibility of 
strings can be as low as 28% after caesarean insertion. [8] In a large observational trial by 
FIGO conducted in 6 low-income countries (2018), missing strings were 2.88 times more 
common following insertion at C/S as compared to vaginal delivery. [10] 
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An ultrasound was performed in 67.5% of women. The GSH family planning unit scan most 
women at the 6 weeks visit, whereas an ultrasound was only performed in the instance of lost 
strings or symptoms at NSH. The continuation rate between the two hospitals was not 
significantly different even though the scan rate was higher at GSH. Our follow-up groups 
were however too small to draw any definitive conclusions regarding this. Three patients 
(3/52) in whom ultrasounds were performed were found to have had undetected expulsions. 
The absence of visible strings is an important clue to this, and availability of ultrasound is 
important in these patients. One patient presented with a twin pregnancy three months after 
insertion due to undetected expulsion. The importance of follow-up must be emphasised in 
our patient population, since they may experience pregnancy as failure of the device, whereas 
it was actually failure of attending F/U leading to undetected expulsion. 
The IUD was normally positioned in 63.5% of women where ultrasound was performed. The 
removal rate due to ultrasound findings alone was 26.3%. This confirms that patients may be 
asymptomatic in some cases of malpositioning. With our high removal rate due to 
asymptomatic malpositioning, routine ultrasound at the 6-weeks visit should be considered 
in all women after intra-caesarean IUD insertion. 
An important finding is the significantly decreased continuation rate after emergency C/S 
(60.5%). Many factors could contribute – prolonged labour and multiple vaginal examinations 
increasing the risk of endomyometritis, the degree of cervical dilatation at the time of 
insertion, and the inflammatory response characteristic of labour triggering contractions. To 
our knowledge no studies have specifically looked at this variable yet and it may need further 
investigation. 
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The expulsion rate was 11.7% (9/77) if we only look at the patients who attended follow-up. 
The partial (5/9) and complete (4/9) expulsion rates were similar. This is slightly higher than 
the expulsion rates in the literature (3.9-10.9%). This may be explained by our small follow-
up group, as well as the possibility of patients with complications or symptoms being more 
likely to attend. Expulsions were increased after emergency C/S, even though not statistically 
significant (p=0.576). Clinician experience at follow-up may play a role in the partial expulsion 
rate – some doctors may be more experienced in performing ultrasound for IUD positioning, 
and may have more strict criteria for the IUD being correctly positioned. Their IUD removal 
rate may be higher where ultrasound is performed. Some may scan everyone at follow-up, 
whereas others may have a higher threshold for performing ultrasound. A standardized 
protocol for follow-up may give more reliable results.  
Continuation rates improved with the experience of the inserters in our study. This highlights 
the importance of training and adequate supervision of junior doctors. Previous uterine 
surgery, cervical dilatation and HIV status did not significantly affect continuation and should 
not be a contraindication to insertion.  
Limitations of the study 
This is a retrospective study relying on information from notes made in hospital folders, 
therefore information is not standardized and is dependent on the nature of the clinical note 
keeping. Some folders were excluded due to poor note keeping as it could not be established 
whether the patients ultimately received the IUD or not. Lost folders may also have 
contributed to the poor F/U rate. The number of patients who attended follow-up were 
exceptionally low, which make findings from the population who followed up less reliable due 
to the small group.  Findings between the two hospitals were similar though, which is 
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reassuring. We could not assess patient satisfaction since this was rarely documented in the 
notes. This important outcome will best be measured in a prospective study. 
Conclusion
The immediate postpartum period may be the only opportunity we have to provide LARC in 
some women. In our patient population follow-up rates are poor, and therefore the side-
effects, expulsion rate, malpositioning and acceptability of the method cannot be accurately 
gauged. Measures must be taken to improve this. A prospective study with a different 
location or method of follow-up may give more information regarding these factors. Where 
the IUD is considered at the time of emergency C/S, patients must be informed about the 
possible lower continuation rate. However, it should still be offered as many patients may 
default follow-up, and the IUD is safe, effective and long-acting.  
Recommendations 
1) Revision and standardization of follow-up protocols. Follow-up at Primary Health Care
Clinics where the patient will attend for her and her baby’s 6 weeks visit may improve
attendance rates.
2) Adequate training of Primary Health Care staff to ensure that they are familiar with
the follow-up care.
3) Ultrasound access at the follow-up facility to efficiently manage patients with
symptoms or lost strings. Where ultrasound is readily available, routine scanning at
the first visit should be considered. Effective referral pathways must be ensured.
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4) Adequate counselling before discharge including:
- possible side-effects (specifically leucorrhoea, spotting, pain and protruding
strings)
- the small risk of unnoticed expulsion and unwanted pregnancy
- the importance of follow-up and what it entails
- an open-door policy for the trimming of strings and management of side-effects.
5) Information leaflets with contact numbers and appointment slips
6) Note keeping about insertion of IUDs and counselling before and after IUD insertion
are medicolegal pitfalls and should receive more attention.
7) Adequate training of junior doctors in the correct insertion techniques.  IUD
placement techniques should be standardised – particularly strings should be fed into
the cervical canal and not trimmed based on the high rate of missing strings.
8) More data is needed regarding the decreased continuation rate after insertion at the
time of emergency C/S. Patients should be informed about this risk.
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Employment   0=unknown   1=yes   2=no 
Income      0=unknown    1=h1    2=h2 
3=h3    4=private 
Marital status 0=unknown  1=single 
2=married         3=partner  
Contraceptive counselling time    0=none 
1=antenatal 2=labour 3=at C/S 
4=unknown 
Caesar type 1=elective 2=emergency 
3=unknown 
Emergency indication      0=unknown   
1=fetal distress 2=malpresentation 3=FTP  
4=twins     5=failed IOL  6=PET  7=c/sx1 
8=c/s>1 9=post-term  10=macrosomia    
11=labour   12=APH 13=prev 3rd deg tear 
Emergency indication   0=unknown      
1=fetal distress   2=malpresentation   
3=FTP   4=twins   5=failed IOL   6=PET   
7=c/sx1   8=c/s>1   9=post-term   
10=macrosomia   11=labour   12=APH 
13=prev 3rd deg tear 
Previous cs  0=0  1=1  2=2  3=>2 
4=unknown 
Number of vaginal examinations in 
labour. 
Booking 0=unknown 1=booked 
2=unbooked 
HIV status    0=unknown    1=positive 
2=negative 
Viral load     0=unknown   1=<1000  
2=>1000 
Cervical dilatation at time of delivery 
(cm). 
IUD inserted by: 0=unknown 
1=consultant   2=senior registrar 3=junior 
registrar  4= medical officer 5=COSMO 
6=intern 
Immediate complications (1) 0=none 
1=fever 2=PPH 3=endometritis 4=wound 
sepsis 5=expulsion 6=removal   7=death   
8=tachycardia 9=hysterectomy 
10=unknown 
Immediate complications (2)   0=none 
1=fever 2=PPH 3=endometritis 4=wound 
sepsis 5=expulsion 6=removal   7=death   
8=tachycardia 9=hysterectomy 
10=unknown 
Days in hospital post-caesarean section 
A review of IUD placement 
during caesarean section at 
level two facilities in the 
Metro West area. 
University of Cape Town 
MMED: Dr. Marcelle Schutte 
SCHMAR 170 
Placement date: __________ 
Data collection date: 
________________________ 




Follow up at 6 weeks  1=attended 2=not attended   
3=attended elsewhere in system   4=IUCD removed 
earlier  5=demised 
Timing of attendance post-insertion: 1=<2 months  
2=2-3 months  3=>3 months  4=unknown 5=expelled 
earlier 
Side effects at follow-up(1)  0=none 1=bleeding 
2=pain 3=discharge 4=infection 5=pregnancy  
6=unknown 7=expulsion 8=protruding strings     
Side effects at follow-up(2)   0=none 1=bleeding 
2=pain 3=discharge 4=infection 5=pregnancy  
6=unknown 7=expulsion 8=protruding strings    
Side effects at follow-up(3)   0=none 1=bleeding 
2=pain 3=discharge 4=infection 5=pregnancy  
6=unknown   7=expulsion 8=protruding strings 
Expulsion  0=none 1=partial 2=complete  3=unknown 
Strings  1=visible  2=not visible  3=unknown 
Ultrasound   1=done 2=not done  3=unknown 
Ultrasound distance from  fundus:  0=not specified 
1=fundal   2=>20mm from fundus   3=not seen 
Ultrasound position  0=not specified 1=normal  
2=rotated 3=oblique/inverted 4=lateral  5=not seen 
Continuation at week 6    0=unknown 1=yes 2=no 
Removal at 6 week  visit   0=unknown 1=yes 2=no 
3=expelled earlier 
Reason for removal   0=not removed 1=ultrasound  
2=symptoms   3=ultrasound and symptoms  4=pt 
request  5=other  6=unknown 7=clinical findings 
8=expelled 
Specific indication for removal(1)                0=not 
removed  1=pain  2=bleeding 3=infection 4=pt 
request 5=failure 6=malposition 7=not specified 
8=unknown 9=expelled 
Specific indication for removal(2)                0=not 
removed  1=pain  2=bleeding 3=infection 4=pt 




UNIVERSITY OF CAPE TOWN 
Faculty of Health Science■ 
Human Research Ethic■ Committee 
R,oom E53•48 Old Main Bulldlns 
Groote Schuur Hoaplta 
ObNrvatory 792! 
Telephone [021] 406 649� 
Emall: symayah,adefdleo@yct.ac,ze 
Web•lte: www,health.uct,oc,za/fhs/research/humanethlc;slfocm! 
24 August 2018 
HREC REF: 542/2018 
Dr M Patel 
Head: Reproductive Medicine& Fertillty Regulation 
Obstetrics & Gynaecology 
H-Floor 
0MB 
Dear Dr Patel 
PROJECT TITLE: A REVIEW OF INTRA-UTERINE DEVICE PLACEMENT DURING CAESAREAN 
SECTION IN THE METRO WEST AREA (MMED CANDIDATE • DR M SCHUTTE) 
Thank you for submitting your study to the Faculty of Health Sciences Human Research Ethics 
Committee (HREC) for review. 
It Is a pleasure to Inform you that the HREC has formally approved the above-mentioned study. 
Approval i  granted for one year untll the 30 August 2019. 
Please submit a progress form, using the standardised Annual Report Form If the study continues 
beyond the approval period. Please submit a Standard Closure form If the study Is completed within the 
approval period. 
(Forms can be found on our website: www.health.uct.ac,za/fhs/research/humanethlcs/forms) 
We acknowledge that the student: Dr Marcelle Schutte will also be Involved In this .tudy. 
Please quote the HR!C REF In all your corre pondence. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
Investigator. 
Please note that for all studies approved by the HREC, the principal investigator JDJ1B obtain appropriate 
Institutional approval, where necessary, before the research may occur. 
Yours slncerely 
OF SOR M LOC . AN 
CHAIRPERSON, fHS HUMAN RESEARCH ETHICS COMMM!E 
Federal Wide Assurance Number: FWA00001637. 
Instltutlonal Review Board (IRB) number: IRB00001938 
Signature removed
This serves to confirm that the University of cape Town Human Research Ethics Committee complies 
to the Ethics Standards for Clinical Research with a new drug In patients, based on the Medical 
Research Council (MRC-SA), Food and Drug Administration (FDA-USA), International Convention on 
Harmonisation Good Cllnical Practice (ICH GCP), South African Good Cllnlcal Practice Guidelines (DoH 
2006), based on the Association of the British Pharmaceutical Industry Guidelines (ABPI), and 
Declaration of Helsinki (2013) guidelines. 
The Human Research Ethics Committee granting this approval is In compliance with the ICH 
Harmonised Tripartite Guidelines E6: Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) 
and FDA Code Federal Regulation Part SO, 56 and 312. 
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ENQUIRIES: Dr Sabela Petros 
University of C a p e  Town 
Anzio Road 
Observatory 
C a p e  Town 
7925 
Health impact assessment 
Health research sub-directorate 
Healf h. Research@wesf erncape .gov .za 
Tel: +27 21 483 0866: fax: +27 21 483 9895 
5th Floor, Norfon Rose House, 8 Riebeek S1ree1, Cape Town, 800 I 
www.capeqafeway.gov .za) 
For attention: Dr Marcelle Schutte, Dr Malika Patel, Dr Gregory Petro 
Re: A Review of Intra-Uterine Contraceptive Device Placement During Cesarean Section At Level 
Two Facilities In The Metro West Area. 
Thank you for submitting your proposal to undertake the above-mentioned study. We are pleased 
to inform you that the department has granted you approval for your research. Please contact 
following people to assist you with any further enquiries in accessing the following sites: 
New Somerset Hospital Dr Donna Stokes 0214026448 
Kindly ensure that the following are adhered to: 
l. Arrangements can be made with managers, providing that normal activities at requested
facilities are not interrupted.
2. By being granted access to provincial health facilities, you are expressing consent to
provide the department with an electronic copy of the final feedback (annexure 9) within
six months of completion of your project. This can be submitted to the provincial Research
Co-ordinator (Health.Research@westerncape.gov.za).
3. In the event where the research project goes beyond the estimated completion date
which was submitted, researchers are expected to complete and submit a progress report
(Annexure 8) to the provincial Research Co-ordinator
(Health.Research@westerncape.gov.za).
4. The reference number above should be quoted in all future correspondence.
Yours sincerely 
MS A VAN DEN B 
ACTING DIRECTOR: HEALTH IMPACT 
ASSESSMENT DATE:  
Signature Removed
Appendix 4:
Mowbray Maternity Hospital Approval Letter
REFERENCE:WC_201810_013 
ENQUIRIES: Dr Sabela Petros 





Health impact assessment 
Health research sub-directorate 
Heal1h.Research@wes1erncape.gov.za 
Tel: +27 21 483 0866: fax: +27 21 483 9895 
51h Floor, Norton Rose House, 8 Riebeek Stree1, Cape Town, 8001 
www.capega1eway.gov .za) 
For attention: Dr Marcelle Schutte, Dr Malika Patel, Dr Gregory Petro 
Re: A Review of Intra-Uterine Contraceptive Device Placement During Cesarean Section At Level 
Two Facilities In The Metro West Area. 
Thank you for submitting your proposal to undertake the above-mentioned study. We are pleased 
to inform you that the department has granted you approval for your research. Please contact 
following people to assist you with any further enquiries in accessing the following sites: 
Mowbray Maternity Hospital Dr Chantal Stewart 021 659 5579 
Kindly ensure that the following are adhered to: 
l. Arrangements can be made with managers, providing that normal activities at  requested
facilities are not interrupted.
2. By being granted access to provincial health facilities, you are expressing consent to
provide the department with an electronic copy of the final feedback (annexure 9) within
six months of completion of your project. This can be submitted to the provincial Research
Co-ordinator (Health.Research@westerncape.qov.za).
3. In the event where the research project goes beyond the estimated completion date
which was submitted, researchers are expected to complete and submit a progress report
(Annexure 8) to the provincial Research Co-ordinator
(Health.Research@westerncape.gov .za).
4. The reference number above should be quoted in all future correspondence.
Yours sincerely 
DRM MOODLEY 









ENQUIRIES: Dr Sabela Petros 
University of C a p e  Town 
Anzio Road 
Observatory 
C a p e  Town 
7925 
Health impact assessment 
Health research sub-directorate 
Healf h. Research@wesf erncape .gov .za 
Tel: +27 21 483 0866: fax: +27 21 483 9895 
5th Floor, Norfon Rose House, 8 Riebeek S1ree1, Cape Town, 800 I 
www.capeqafeway.gov .za) 
For attention: Dr Marcelle Schutte, Dr Malika Patel, Dr Gregory Petro 
Re: A Review of Intra-Uterine Contraceptive Device Placement During Cesarean Section At Level 
Two Facilities In The Metro West Area. 
Thank you for submitting your proposal to undertake the above-mentioned study. We are pleased 
to inform you that the department has granted you approval for your research. Please contact 
following people to assist you with any further enquiries in accessing the following sites: 
New Somerset Hospital Dr Donna Stokes 0214026448 
Kindly ensure that the following are adhered to: 
l. Arrangements can be made with managers, providing that normal activities at requested
facilities are not interrupted.
2. By being granted access to provincial health facilities, you are expressing consent to
provide the department with an electronic copy of the final feedback (annexure 9) within
six months of completion of your project. This can be submitted to the provincial Research
Co-ordinator (Health.Research@westerncape.gov.za).
3. In the event where the research project goes beyond the estimated completion date
which was submitted, researchers are expected to complete and submit a progress report
(Annexure 8) to the provincial Research Co-ordinator
(Health.Research@westerncape.gov.za).
4. The reference number above should be quoted in all future correspondence.
Yours sincerely 
MS A VAN DEN B 




Groote Schuur Hospital Approval Letter
GROOTE SCHUUR HOSPITAL 
Enquiries: Dr Bernadette Eick 
E-mail : Bernadette.Eick@westerncape.gov.za
G46 Management Suite, Old Main Building, Private Bag X,  
Observatory 7925  Observatory, 7935 
Tel: +27 21 404 6288    fax: +27 21 404 6125 www.capegateway.go.v.za 
Dr M. Patel 
OBSTETRIC & GYNAECOLOGY 
E-mail: m.patel@uct.ac.za / marcelleschutte@gmail.com / Gregory.Petro@westerncape.gov.za
Dear Dr Patel 
RESEARCH PROJECT: A Review of IUCD Placement During Caesarean Section At Level Two Facilities In 
The Metro West Area 
Your recent letter to the hospital refers. 
You are granted permission to proceed with your research, which is valid until 30 August 2019. 
Please note the following: 
a) Your research may not interfere with normal patient care.
b) Hospital staff may not be asked to assist with the research.
c) No additional costs to the hospital should be incurred i.e. Lab, consumables or stationary.
d) No patient folders may be removed from the premises or be inaccessible.
e) Please provide the research assistant/field worker with a copy of this letter as verification of
approval.
f) Confidentiality must be maintained at all times.
g) Should you at any time require photographs of your subjects, please obtain the necessary
indemnity forms from our Public Relations Office (E45 OMB or ext. 2187/2188).
h) Should you require additional research time beyond the stipulated expiry date, please apply for
an extension.
i) Please discuss the study with the HOD before commencing.
j) Please introduce yourself to the person in charge of an area before commencing.
k) On completion of your research, please forward any recommendations/findings that can be
beneficial to use to take further action that may inform redevelopment of future policy / review
guidelines.
l) Kindly submit a copy of the publication or report to this office on completion of the research.
I would like to wish you every success with the project. 
Yours sincerely 
DR BERNADETTE EICK 
CHIEF OPERATIONAL OFFICER 
Date: 26 September 2018 
C.C. Mr L. Naidoo 
Professor E. Weimann 
Professor L. Denny 
Signature Removed
Appendix 7: 
Instructions For Authors O&G Forum 
Material submitted for publication in the O&G Forum is
accepted on condition that it meets the requirement of the editor
in chief. The publisher reserves the copyright of the material
published. All authors must give consent to publication, and the
O&G Forum does not hold itself responsible for statements
made by contributors.
The Journals primary aim is the publication of review and
original articles, case reports and letters to the editor aimed at
specialist obstetricians and gynaecologists and other
professionals working as primary care practitioners. All material
will be sent for peer review.
Manuscript preparation
1. Copies should be neatly typewritten, with double spacing
and wide margins. The manuscript should be submitted
electronically. Authors are required to state that their material
is original and not previously published or currently
submitted elsewhere.
2. All abbreviations should be spelt out when first used in the
text and thereafter used consistently.
3. Scientific measurements should be expressed in SI units
throughout, with two exceptions: blood pressure should be
given in mmHg and haemoglobin values in g/dl.
4. Author’s full name & surname, affiliation & correspondence
address (including email address) to be set out in full on title
page of article.
5. All articles (review, original research etc) are to have an
abstract, giving a brief succinct overview of the article. The
abstract should reflect the essence of the paper and be 200
to 250 words. For Original Research articles, the abstract
should be structured as follows:- Objective, Method, Results
and Conclusion.
6. Authors must give a minimum of three key words, and
should use the MeSH (Medical subject headings list of
index medicus) cataloque.
7. A clear statement on ethical issues in clinical and animal
research must be provided; conflict of interests and patient
confidentiality issues must be indicated.
8. For multi authored papers, the International Committee of
Medical Journal Editors (ICMJE) states that, there are three
necessary conditions one must meet in order to claim (co)
authorship:
1. Substantial contributions to conception and design, or
acquisition of data, or analysis and interpretations of data.
2. Drafting the article or revising it critically for important
intellectual content.
3. Final approval of the version to be published.
Those, and only those who meet all three of the above
stipulations, can be named authors, while those who meet only
some of the requirements or otherwise facilitate the research by
contributing to funding, data collection, editorial work, etc. should
be named in the ‘Acknowledged’ section.
Accordingly, multi-authored papers need a declaration of relative
contribution.
Illustrations
1. Figures consist of all material which cannot be set in type,
such as photographs and line drawings. Photographs should
be forwarded electronically.
2. Tables and legends for illustrations should be typed on
separate sheets and should be clearly identified. Tables
should carry Roman numerals, thus I, II, III, etc, and
illustrations Arabic numerals, thus: 1, 2, 3, etc.
3. Where identification of a patient is possible from a photograph
the author must submit a consent to publication signed by the
patient, or by the parent or guardian in the case of a minor.
4. If any tables or illustrations submitted have been published
elsewhere, written consent to republication should be
obtained by the author from the copyright holder and the
author(s).
References
1. References should be inserted at the end of the sentence,
outside the full stop, as superior numbers, and should be
listed at the end of the article in numerical order.
Do not list them alphabetically.
2. It is the author’s responsibility to verify references from the
original sources.
3. References should be set out in the Vancouver style, and
only approved abbreviations of journal titles should be used;
consult the List of Journals Indexed in Index Medicus for
these details. Names and initials of all authors should be
given unless there are more than six, in which case the six
names should be given followed by “et al”. First and last
page numbers should be given.
Journal references should appear as follows:
a. Peter S. Acute hamstring injuries. Am J Sports Med 1994;
12(7):395-400.
Book references should be set out as follows:
a. Williams G. Textbook of Sports Medicine. 2nd Edition:
Butterworth, 1989: 101-104.
b. Vandermere P, Russel P. Biomechanics of the hip joint.
In:Nordien PE. Jeffcoat A, eds, Clinical Biomechanics.
Philadelphia:WB Saunders, 1990:472-479.
4. “Unpublished observations” and “personal communications”
may be cited in the text, but not in the reference list.
Manuscripts accepted but not yet published can be included
as references followed by “(in press)”.
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